Literature DB >> 29275308

Early PET-CT After Stereotactic Radiotherapy for Stage 1 Non-small Cell Lung Carcinoma Is Predictive of Local Control.

Marguerite Tyran1, Nathalie Charrier2, Julien Darreon1, Anne Madroszyk3, Agnes Tallet1, Naji Salem4.   

Abstract

BACKGROUND/AIM: Radiological evaluation after stereotactic-body-radiotherapy (SBRT) for non-small-cell lung carcinoma (NSCLC) is often difficult due to lung radiation-induced image modifications on computed tomographic (CT) scan. The aim of this study was to evaluate positron-emission tomography-computed tomography (PET-CT) using fluorodeoxyglucose after SBRT in primary lung cancer. PATIENTS AND METHODS: Eighteen patients with histologically proven NSCLC were treated with SBRT. All had PET-CT evaluations before treatment, at 2 to 3 months and at 1 year post SBRT during the follow-up.
RESULTS: Early PET-CT in 12/18 patients who did not experience local failure did not show any progression. No conclusion could be drawn in four cases because early PET-CT was disturbed by inflammatory reaction. Early PET-CT was not predictive of late outcome for two patients, as it showed a significant response followed by disease progression on late evaluation.
CONCLUSION: Early PET response appears to correlate with local control at 1 year post SBRT. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Lung cancer; PET-computed tomographic; SBRT; local control

Mesh:

Year:  2018        PMID: 29275308      PMCID: PMC5892649          DOI: 10.21873/invivo.11213

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  26 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

Authors:  J Vansteenkiste; L Crinò; C Dooms; J Y Douillard; C Faivre-Finn; E Lim; G Rocco; S Senan; P Van Schil; G Veronesi; R Stahel; S Peters; E Felip
Journal:  Ann Oncol       Date:  2014-02-20       Impact factor: 32.976

3.  Radiological changes after stereotactic radiotherapy for stage I lung cancer.

Authors:  Max Dahele; David Palma; Frank Lagerwaard; Ben Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2011-07       Impact factor: 15.609

4.  Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?

Authors:  Katy Clarke; Mojgan Taremi; Max Dahele; Marc Freeman; Sharon Fung; Kevin Franks; Andrea Bezjak; Anthony Brade; John Cho; Andrew Hope; Alexander Sun
Journal:  Radiother Oncol       Date:  2012-06-09       Impact factor: 6.280

5.  Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer.

Authors:  Neal E Dunlap; Wensha Yang; Alyson McIntosh; Ke Sheng; Stanley H Benedict; Paul W Read; James M Larner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-14       Impact factor: 7.038

Review 6.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; Baldassarre Stea; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2010-01-13       Impact factor: 6.280

7.  Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy.

Authors:  M Essler; J Wantke; B Mayer; K Scheidhauer; R A Bundschuh; B Haller; S T Astner; M Molls; N Andratschke
Journal:  Strahlenther Onkol       Date:  2013-04-24       Impact factor: 3.621

8.  A pilot trial of serial 18F-fluorodeoxyglucose positron emission tomography in patients with medically inoperable stage I non-small-cell lung cancer treated with hypofractionated stereotactic body radiotherapy.

Authors:  Mark A Henderson; David J Hoopes; James W Fletcher; Pei-Fen Lin; Mark Tann; Constantin T Yiannoutsos; Mark D Williams; Achilles J Fakiris; Ronald C McGarry; Robert D Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-05-25       Impact factor: 7.038

9.  FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.

Authors:  Pierre Lovinfosse; Zsolt Levente Janvary; Philippe Coucke; Sébastien Jodogne; Claire Bernard; Mathieu Hatt; Dimitris Visvikis; Nicolas Jansen; Bernard Duysinx; Roland Hustinx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-30       Impact factor: 9.236

10.  Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.

Authors:  H Minn; K R Zasadny; L E Quint; R L Wahl
Journal:  Radiology       Date:  1995-07       Impact factor: 11.105

View more
  2 in total

1.  The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer.

Authors:  Qian Li; Yu Liu; Bin Su; Hongguang Zhao; Qingren Lin; Yaoyao Zhu; Lingnan Zhang; Denghu Weng; Xiaomei Gong; Xiaojiang Sun; Yaping Xu
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 2.  Evaluation of tumor response after stereotactic body radiation therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Pino Alcantara; Beatriz Cabeza Martínez; Marta García García-Esquinas; Laura G Belaústegui; Ana Bustos
Journal:  J Clin Transl Res       Date:  2020-10-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.